Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

• Published in: Journal of hematology and oncology Vol. 15; no. 1; p. 79
• Main Authors: Fujino, Toshio, Suda, Kenichi, Koga, Takamasa, Hamada, Akira, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.06.2022; BioMed Central; BMC
• Subjects: Analysis; Anilides; Benzamides; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Cell culture; Cell growth; Cloning; Crizotinib; Drug Resistance, Neoplasm - genetics; Drugs; Exons; Gene mutations; Genetic aspects; Hematology; Humans; Imidazoles; Kinases; Ligands; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical research; Molecular dynamics; Mutagenesis; Mutation; Non-small cell lung carcinoma; Oncology; Patients; Piperidines; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proteins; Proto-Oncogene Proteins c-met - genetics; Pyridazines; Pyrimidines; Quinolines; Small cell lung carcinoma; Triazines; Japan
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-022-01299-z

Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14. The inhibitory effects of 300 drugs, including 33 MET-TKIs, were screened in Ba/F3 cells carrying METex14 plus MET D1228A/Y secondary mutations. The screen revealed four-candidate type II MET-TKIs (altiratinib, CEP-40783, foretinib and sitravatinib). Therefore, we performed further growth inhibitory assays using these four MET-TKIs plus cabozantinib and merestinib in Ba/F3 cells carrying MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations. We also performed analyses using Hs746t cell models carrying METex14 (with mutant allele amplification) with/without D1228X or Y1230X in vitro and in vivo to confirm the findings. Furthermore, molecular dynamics (MD) simulations were carried out to examine differences in binding between type II MET-TKIs. All 6 type II MET-TKIs were active against Y1230X secondary mutations. However, among these 6 agents, only foretinib showed potent activity against D1228X secondary mutations of the MET in the Ba/F3 cell and Hs746t in vitro model and Hs746t in vivo model, and CEP-40783 and altiratinib demonstrated some activity. MD analysis suggested that the long tail of foretinib plays an important role in binding D1228X MET through interaction with a residue at the solvent front (G1163). Tertiary G1163X mutations, together with L1195F/I and F1200I/L, occurred as acquired resistance mechanisms to the second-line treatment foretinib in Ba/F3 cell models. The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230.